M&A

News

Datavant and Aetion merger promises "faster, more actionable" real-world data insights across pharma's clinical and commercial lifecycle.

News

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

News

Shionogi has reached a $1.04bn agreement to buy Torii, the pharma subsidiary of Japan Tobacco, as it tries to meet an ambitious sales target.

News

Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.

News

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.

News

Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share.